GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » EV-to-EBITDA

OptimizeRx (OptimizeRx) EV-to-EBITDA : -8.90 (As of Apr. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OptimizeRx's enterprise value is $189.54 Mil. OptimizeRx's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.31 Mil. Therefore, OptimizeRx's EV-to-EBITDA for today is -8.90.

The historical rank and industry rank for OptimizeRx's EV-to-EBITDA or its related term are showing as below:

OPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15519.04   Med: -28.21   Max: 609.81
Current: -8.9

During the past 13 years, the highest EV-to-EBITDA of OptimizeRx was 609.81. The lowest was -15519.04. And the median was -28.21.

OPRX's EV-to-EBITDA is ranked worse than
100% of 460 companies
in the Healthcare Providers & Services industry
Industry Median: 13.195 vs OPRX: -8.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), OptimizeRx's stock price is $8.80. OptimizeRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.020. Therefore, OptimizeRx's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


OptimizeRx EV-to-EBITDA Historical Data

The historical data trend for OptimizeRx's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx EV-to-EBITDA Chart

OptimizeRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -81.73 -7,869.32 418.71 -22.61 -13.27

OptimizeRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.61 -13.90 -12.67 -4.84 -13.27

Competitive Comparison of OptimizeRx's EV-to-EBITDA

For the Health Information Services subindustry, OptimizeRx's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptimizeRx's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OptimizeRx's EV-to-EBITDA falls into.



OptimizeRx EV-to-EBITDA Calculation

OptimizeRx's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=189.536/-21.308
=-8.90

OptimizeRx's current Enterprise Value is $189.54 Mil.
OptimizeRx's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OptimizeRx  (NAS:OPRX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

OptimizeRx's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.80/-1.020
=At Loss

OptimizeRx's share price for today is $8.80.
OptimizeRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.020.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


OptimizeRx EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of OptimizeRx's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


OptimizeRx (OptimizeRx) Business Description

Traded in Other Exchanges
N/A
Address
400 Water Street, Suite 200, Rochester, MI, USA, 48307
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Executives
Marion Odence-ford officer: General Counsel and CCO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco officer: Chief Commercial Officer 260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch officer: Chief Product Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo officer: Chief Executive Officer 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro officer: Chief Commercial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh officer: COO and CFO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore officer: President 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler director, officer: SVP of Product & Strategy 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker officer: Chief Financial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman officer: Chief Technology Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson director 200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas director 38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022